Clinical Trial UCI-16-52 Click to view printable page

Title

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Principal Investigator

Krishnansu Tewari

Details

Learn More

For information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email ucstudy@uci.edu

If you would like more information regarding this specific trial, please leave your name, phone number, and email. We will contact you promptly.

Name: Email: Phone: